Ivana Sestak

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2016-2021
Publications (10 Years): 4

Top Topics

Bone Mineral Density

Sentinel Lymph Node

Top Venues

Breast cancer research and treatment

NPJ breast cancer

British journal of cancer

Queen Mary University of London

Queen Mary University of London (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Queen Mary University of London

United Kingdom

Associated Professor in Medical Statistics :: Centre for Cancer Prevention

Education History

Queen Mary University of London

United Kingdom

PHD :: Wolfson Institute of Preventive Medicine

Swiss Federal Institute of Technology

Switzerland

MSC :: Biotechnology

Publications

Richard Buus, Zsolt Szijgyarto, Eugene F Schuster, Hui Xiao, Ben P Haynes, Ivana Sestak, Jack Cuzick, Laia Paré, Elia Seguí, Nuria Chic, Aleix Prat, Mitchell Dowsett, Maggie Chon U Cheang
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®. NPJ breast cancer 7 (1) (2021)
Ivana Sestak, Glen Blake, Raj Patel, Jack Cuzick, Anthony Howell, Robert Coleman, Richard Eastell
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. British journal of cancer 124 (8) (2021)
Ivana Sestak, Miguel Martín, Peter Dubsky, Ralf Kronenwett, Federico Rojo, Jack Cuzick, Martin Filipits, Amparo Ruiz, William Gradishar, Hatem Soliman, Lee Schwartzberg, Richard Buus, Dominik Hlauschek, Alvaro Rodríguez-Lescure, Michael Gnant
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast cancer research and treatment 176 (2) (2019)
Ivana Sestak, Mitch Dowsett, Sean Ferree, Frederick L Baehner, Jack Cuzick
Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors. Breast cancer research and treatment 159 (1) (2016)